Beyond Micronization - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Beyond Micronization
Emerging methods could provide alternative ways of producing inhalable drug particles.


Pharmaceutical Technology
Volume 35, Issue 5, pp. 52-54

In addition, SAS results in particles that have highly desirable properties for inhalation medicines. The particles generally are smaller than 10 m and have a narrow size distribution. The process is tunable and can make 1–3-m particles (e.g., for targeting the deep lung) or 3–5-m particles (e.g., for targeting the upper respiratory airways). Particles made through SAS also are highly crystalline, free from amorphous domains, and, thus, highly stable. The particles' surfaces tend to be smooth and regular with low surface energy, and these characteristics reduce agglomeration and help improve downstream handling.

In the past 15 years, technology has advanced to the point where SAS can produce materials at manufacturing scale that comply with cGMP. New developments at CrystecPharma enable composite particles containing defined ratios of two or more drug substances (e.g., for combined drug therapy) to be manufactured. Clinical evidence indicates that SAS improves the performance of drug materials, compared with other manufacturing techniques. Products containing SAS-processed particles have improved drug bioavailability, led to simplified formulations, and reduced required doses, says York.

SAS also is superior to micronization in several ways. During micronization, particles are bombarded against the walls of a mill, and this intensive process can create high-energy sites on the surfaces of the materials being milled. These high-energy sites can cause potential chemical or physical changes in the material. One of the most problematic changes is the introduction of noncrystalline or amorphous domains in the product, which can reduce its stability. Micronized material also has highly charged surfaces and tends to be cohesive and difficult to disperse into an aerosol, says York.

Yet many drugmakers might be reluctant to abandon micronization because they have years of experience with the process—and have invested considerable sums into the technology and training required. The industry's overall conservatism and antipathy to change also could slow companies' adoption of SAS, in spite of the method's advantages.

If FDA approves Levadex, however, it would be the first product on the market manufactured through SAS. "That will take the risk out of these processes for a lot of potential clients," says York.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
30%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
8%
All of the above.
45%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here